Site-specific binding constants for actinomycin D on DNA determined from footprinting studies

Area of Science:

• Molecular Biology
• Biochemistry
• Pharmacology

Background:

• Actinomycin D (Act-D) is an intercalating anticancer drug with known DNA-binding properties.
• Understanding site-specific binding is crucial for elucidating drug efficacy and mechanisms of action.
• Previous studies have not precisely quantified binding constants for Act-D at individual DNA sites.

Purpose of the Study:

• To determine site-specific binding constants for actinomycin D (Act-D) on a defined DNA fragment.
• To identify and characterize the DNA sequences that represent strong and weak binding sites for Act-D.
• To develop a model for interpreting DNA footprinting data to quantify drug-DNA interactions.

Main Methods:

• Utilized DNase I footprinting experiments on a 139-base-pair DNA fragment derived from pBR 322.
• Measured cleavage product intensities via gel electrophoresis and autoradiography across varying Act-D concentrations.
• Employed a detailed model accounting for drug binding effects and carrier DNA to derive binding constants.

Main Results:

• Identified 14 distinct strong and weak binding sites for Act-D within the 139-bp DNA fragment.
• Determined site-specific binding constants, with the highest observed for the TGCT sequence (6.4 x 10^6 M^-1).
• Found that GC-rich sequences, particularly TGCT, represent the strongest binding sites; GGC sequences showed weaker binding.

Conclusions:

• Actinomycin D exhibits sequence-specific DNA binding, with a strong preference for GC-rich regions.
• The study provides quantitative binding constants, advancing the understanding of Act-D's interaction with DNA.
• The findings contribute to understanding the mechanism of action for this important anticancer drug.